Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation

Tanush Gupta; Byomesh Tripathi; Ankur Kalra; Sahil Khera; Abhishek Sawant; Tamim M. Nazif; Neal S. Kleiman; Ajay J. Kirtane; Sachin S. Goel; Deepak L. Bhatt; Ashish Pershad; Susheel K. Kodali

doi:10.1016/j.amjcard.2021.12.049

Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation

Tanush Gupta, Byomesh Tripathi, Ankur Kalra, Sahil Khera, Abhishek Sawant, Tamim M. Nazif, Neal S. Kleiman, Ajay J. Kirtane, Sachin S. Goel, Deepak L. Bhatt, Ashish Pershad, Susheel K. Kodali

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	167-170
Number of pages	4
Journal	American Journal of Cardiology
Volume	167
DOIs	https://doi.org/10.1016/j.amjcard.2021.12.049
State	Published - 15 Mar 2022

Access to Document

10.1016/j.amjcard.2021.12.049

Cite this

@article{66da85ff431c4dc795b6033c916c5cf3,

title = "Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation",

author = "Tanush Gupta and Byomesh Tripathi and Ankur Kalra and Sahil Khera and Abhishek Sawant and Nazif, {Tamim M.} and Kleiman, {Neal S.} and Kirtane, {Ajay J.} and Goel, {Sachin S.} and Bhatt, {Deepak L.} and Ashish Pershad and Kodali, {Susheel K.}",

note = "Funding Information: Dr. Deepak L. Bhatt discloses the following relationships: Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE II), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Level Ex, MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and United States national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. Dr. Ajay J. Kirtane reports institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical Interface addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for speaking engagements and/or consulting; no speaking/consulting fees were personally received. Personal: Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron Pharmaceuticals. All other authors have no relevant conflicts of interest to declare.",

year = "2022",

month = mar,

day = "15",

doi = "10.1016/j.amjcard.2021.12.049",

language = "English",

volume = "167",

pages = "167--170",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Trends in 30-Day and 90-Day Readmission Rates After Transcatheter Aortic Valve Implantation

AU - Gupta, Tanush

AU - Tripathi, Byomesh

AU - Kalra, Ankur

AU - Khera, Sahil

AU - Sawant, Abhishek

AU - Nazif, Tamim M.

AU - Kleiman, Neal S.

AU - Kirtane, Ajay J.

AU - Goel, Sachin S.

AU - Bhatt, Deepak L.

AU - Pershad, Ashish

AU - Kodali, Susheel K.

N1 - Funding Information: Dr. Deepak L. Bhatt discloses the following relationships: Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE II), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Level Ex, MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and United States national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. Dr. Ajay J. Kirtane reports institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical Interface addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for speaking engagements and/or consulting; no speaking/consulting fees were personally received. Personal: Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron Pharmaceuticals. All other authors have no relevant conflicts of interest to declare.

PY - 2022/3/15

Y1 - 2022/3/15

UR - http://www.scopus.com/inward/record.url?scp=85125136126&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2021.12.049

DO - 10.1016/j.amjcard.2021.12.049

M3 - Letter

C2 - 35063274

AN - SCOPUS:85125136126

SN - 0002-9149

VL - 167

SP - 167

EP - 170

JO - American Journal of Cardiology

JF - American Journal of Cardiology

ER -